Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

68.50USD
4:00pm EDT
Change (% chg)

$0.09 (+0.13%)
Prev Close
$68.41
Open
$68.52
Day's High
$68.96
Day's Low
$68.40
Volume
1,048,762
Avg. Vol
1,450,052
52-wk High
$68.96
52-wk Low
$51.37

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $120,013.00
Shares Outstanding(Mil.): 1,754.32
Dividend: 0.28
Yield (%): 1.64

Financials

  ABT.N Industry Sector
P/E (TTM): 52.32 30.14 32.45
EPS (TTM): 1.31 -- --
ROI: 3.73 12.95 12.63
ROE: 7.40 14.92 14.80

Abbott Labs raises 2018 earnings forecast, shares hit record high

Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions.

Jul 18 2018

UPDATE 2-Abbott Labs raises 2018 earnings forecast, shares hit record high

* Shares hit record high (Adds details from conference call, analysts' quotes, updates shares)

Jul 18 2018

Abbott Labs tops profit estimates, raises full-year earnings forecast

July 18 Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts' estimates, powered by higher sales across its businesses, including its top-earning medical device unit.

Jul 18 2018

Allergan appoints former Abbott executive to its board

Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

Jun 14 2018

Allergan appoints former Abbott executive to its board

June 14 Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

Jun 14 2018

BRIEF-Abbott's Investigational Tendyne Device For Mitral Valve Replacement Demonstrates Positive Outcomes At 30 Days In Global Study

* ABBOTT'S INVESTIGATIONAL TENDYNE™ DEVICE FOR MITRAL VALVE REPLACEMENT DEMONSTRATES POSITIVE OUTCOMES AT 30 DAYS IN GLOBAL STUDY

May 23 2018

BRIEF-5-Year Study Data Confirm Positive Outcomes For Patients When Abbott Diagnostic Tool Was Used To Guide Heart Stenting Decisions

* FIVE-YEAR STUDY DATA CONFIRM POSITIVE OUTCOMES FOR PATIENTS WHEN ABBOTT DIAGNOSTIC TOOL WAS USED TO GUIDE HEART STENTING DECISIONS Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter

* ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO WITH FDA CLEARANCE OF ADVANCED MAPPING CATHETER

May 03 2018

UPDATE 2-Outgoing Smith & Nephew CEO signs off with a downgrade

* Shares fall 7 pct (Adds CEO comments, analyst reaction, shares)

May 03 2018

BRIEF-Abbott's Xience Sierra Heart Stent Receives National Reimbursement In Japan

* ABBOTT'S XIENCE SIERRA™ HEART STENT RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:

May 02 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $140.46 -0.08
Pfizer Inc. (PFE.N) $43.26 -0.25
Novartis AG (NOVN.S) CHF81.74 +0.28
Merck & Co., Inc. (MRK.N) $69.98 -0.44
Sanofi SA (SASY.PA) €75.12 --
AstraZeneca plc (AZN.L) 5,601.00 -8.00
GlaxoSmithKline plc (GSK.L) 1,496.80 +10.00
Eli Lilly And Co (LLY.N) $105.74 -1.14
Amgen, Inc. (AMGN.OQ) $203.20 +0.86
Boston Scientific Corporation (BSX.N) $37.49 -0.13

Earnings vs. Estimates